Peptide Encyclopedia / NAD+
EncyclopediaNAD+ is a coenzyme central to cellular energy metabolism and a substrate for sirtuins and PARPs. The FDA has not approved any injectable or IV NAD+ product, compounding pharmacies and wellness clinics supply it, and a 2025 Class I recall flagged endotoxin contamination. Educational only, not medical advice.
| Also known as | NAD+, Nicotinamide adenine dinucleotide, Injectable NAD+, IV NAD+, NAD therapy |
| Regulatory status | Injectable/IV NAD+ is NOT FDA-approved for any indication. |
Injectable/IV NAD+ is NOT FDA-approved for any indication. There are no FDA-approved NAD+ products for injection or infusion. It is supplied via compounding pharmacies and IV/wellness clinics. The FDA has flagged NAD+ as an ingredient not on the approved bulk drug substances list for 503B outsourcing facilities, and a Class I recall (most serious level) was issued in 2025 for a compounded NAD+ injection due to elevated endotoxin contamination.
NAD+ (nicotinamide adenine dinucleotide) is a ubiquitous coenzyme central to cellular redox reactions and energy metabolism (glycolysis, TCA cycle, oxidative phosphorylation) and serves as a substrate for sirtuins, PARPs, and CD38. The therapeutic rationale for supplementation is that NAD+ levels decline with age and metabolic stress, and that restoring NAD+ may support mitochondrial function and DNA repair. Whether IV/injected NAD+ itself meaningfully raises intracellular NAD+ (versus being metabolized to precursors) is not well established in humans. Pharmacokinetics (half-life No well-validated human pharmacokinetic half-life established for IV/injectable NAD+; circulating NAD+ is rapidly metabolized and turned over.): Given IV (often as slow multi-hour infusions) or subcutaneously. NAD+ does not readily cross cell membranes intact and is rapidly degraded extracellularly to precursors (e.g., nicotinamide) that are then taken up and resynthesized intracellularly. Rigorous human PK data for injectable NAD+ are lacking. No verified human PK half-life found.
High-quality human efficacy evidence for injectable/IV NAD+ is very limited. Most controlled human metabolic data concern oral NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) rather than IV NAD+ itself; benefits for the anti-aging, addiction-recovery, and energy claims commonly marketed are not established by robust trials of the injectable form. Honest level: limited-human/anecdotal for the injectable product. Reported use: Clinic-reported protocols involve IV infusions (commonly cited in the range of roughly 250-1000 mg per session over several hours, given as single or multi-day courses), or subcutaneous/IM dosing in wellness settings, for marketed goals such as 'energy,' cognitive support, and addiction recovery. These are clinic/community-reported, not validated by controlled trials or approved labeling, and are described here only as reported practice.
Infusion-related effects are commonly reported (nausea, flushing, chest/abdominal discomfort, lightheadedness), typically worse with faster infusion rates. The most serious documented risk is product quality: a 2025 FDA Class I recall of compounded NAD+ injection cited elevated endotoxin levels, which can cause serious harm or death; the FDA has also warned that food-grade NAD+ used by some compounders is inappropriate for IV use due to microbial/endotoxin contamination. Sterility and source-quality risk is the dominant safety concern..
Known hypersensitivity to the product or excipients, Use of contaminated/non-sterile or food-grade NAD+ for injection (FDA-flagged hazard).
No well-characterized drug interactions documented in peer-reviewed human literature for injectable NAD+
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. NAD+ may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
